Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
OMNI BIO PHARMACEUTICAL, INC. (OMBP)
|
Add to portfolio |
|
|
|
| Price: |
$0.03
| | Metrics |
| OS: |
40.5
|
M
| |
|
|
| Market cap: |
$1.21
|
M
| |
|
|
|
Net cash:
|
$646.3
|
k
| |
$0.02
|
per share
|
|
EV:
|
$567.6
|
k
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-14 | Mar-31-13 | Mar-31-12 | Mar-31-11 | Feb-28-11 | Mar-31-10 | Feb-28-10 | Mar-31-09 |
| Revenues | -0.1 | -0.1 | 0.0 | 0.0 | 19.7 | 7.4 | 11.5 | 1.3 |
| Revenue growth | -62.7% | -5979.7% | | -100.0% | 71.8% | 479.3% | | -27.3% |
| Cost of goods sold | -3.8 | -11.4 | 0.0 | 0.0 | 19.7 | 7.4 | 0.0 | 1.3 |
| Gross profit | 3.8 | 11.3 | 0.0 | 0.0 | 0.0 | 0.0 | 11.5 | 0.0 |
| Gross margin | -7320.5% | -8186.8% | 0.0% | | 0.0% | 0.0% | 100.0% | 0.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 0.2 | 0.3 | 0.4 | 0.6 | 1.7 | | 1.1 | 0.2 |
| General and administrative | 1.7 | 5.4 | 4.2 | 7.6 | 18.0 | 7.4 | 10.3 | 1.0 |
| EBITA | -1.9 | -6.5 | -5.2 | -8.2 | -26.1 | -13.0 | -17.8 | -2.0 |
| EBITA margin | 3700.7% | 4705.5% | -223012.6% | | -132.4% | -176.1% | -155.6% | -156.5% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | | | | | |
| EBIT | -1.9 | -6.5 | -5.3 | -8.2 | -26.1 | -13.0 | -17.8 | -2.0 |
| EBIT margin | 3710.3% | 4708.5% | -223887.6% | | -132.4% | -176.1% | -155.6% | -156.5% |
| Pre-tax income | -2.5 | -7.5 | -5.4 | -8.2 | -31.2 | -15.5 | -22.9 | -4.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -2.5 | -7.5 | -5.4 | -8.2 | -31.2 | -15.5 | -22.9 | -4.5 |
| Net margin | 4882.4% | 5399.7% | -229791.0% | | -158.2% | -209.9% | -200.1% | -356.9% |
| |
| Diluted EPS | ($0.07) | ($0.23) | ($0.17) | ($0.29) | | ($0.58) | | ($0.25) |
| Shares outstanding (diluted) | 37.3 | 32.0 | 31.4 | 28.3 | | 26.8 | | 18.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|